全球開放式、一體化生物制藥能力和技術賦能平臺,專注于為全球生物制藥公司提供端到端研發服務的上市公司
藥(yao)明生(sheng)物(wu)(股票(piao)代碼:2269.HK)作為(wei)一家香港上市公(gong)司(si),是全(quan)(quan)球(qiu)(qiu)開放式、一體化生(sheng)物(wu)制藥(yao)能(neng)力和技(ji)術(shu)賦能(neng)平(ping)臺。公(gong)司(si)為(wei)全(quan)(quan)球(qiu)(qiu)生(sheng)物(wu)制藥(yao)公(gong)司(si)和生(sheng)物(wu)技(ji)術(shu)公(gong)司(si)提(ti)供(gong)(gong)端(duan)到端(duan)研發服務(wu),幫助任何人、任何公(gong)司(si)發現、開發及生(sheng)產生(sheng)物(wu)藥(yao),實現從概念(nian)到商(shang)(shang)業(ye)化生(sheng)產的全(quan)(quan)過(guo)(guo)程,加速(su)全(quan)(quan)球(qiu)(qiu)生(sheng)物(wu)藥(yao)研發進程,降低研發成本(ben),造福病患。截至2018年12月31日,在(zai)藥(yao)明生(sheng)物(wu)平(ping)臺上研發的綜(zong)合(he)項(xiang)目達205個(ge)(ge),包括97個(ge)(ge)處(chu)于臨床前研究階段(duan),94個(ge)(ge)在(zai)臨床早(zao)期(qi)(I期(qi),II期(qi))階段(duan),13個(ge)(ge)在(zai)后期(qi)臨床(III期(qi))以及1個(ge)(ge)在(zai)商(shang)(shang)業(ye)化生(sheng)產階段(duan)。預計到2022年,公(gong)司(si)在(zai)中(zhong)國(guo)、愛爾蘭、新加坡、美(mei)國(guo)規劃的生(sheng)物(wu)制藥(yao)生(sheng)產基地合(he)計產能(neng)約22萬(wan)升,這將有(you)力促使公(gong)司(si)通過(guo)(guo)健全(quan)(quan)強大的全(quan)(quan)球(qiu)(qiu)供(gong)(gong)應鏈網(wang)絡為(wei)客戶提(ti)供(gong)(gong)符合(he)全(quan)(quan)球(qiu)(qiu)質(zhi)量(liang)標(biao)準的生(sheng)物(wu)藥(yao)。
藥(yao)(yao)明生(sheng)(sheng)(sheng)(sheng)物(wu)是全(quan)(quan)球開放式、一(yi)(yi)體化生(sheng)(sheng)(sheng)(sheng)物(wu)制(zhi)藥(yao)(yao)能力和(he)技術賦能平臺。公(gong)司為全(quan)(quan)球生(sheng)(sheng)(sheng)(sheng)物(wu)制(zhi)藥(yao)(yao)公(gong)司和(he)生(sheng)(sheng)(sheng)(sheng)物(wu)技術公(gong)司提供端(duan)到(dao)(dao)端(duan)研發服(fu)務,幫助任何人、任何公(gong)司發現、開發及生(sheng)(sheng)(sheng)(sheng)產生(sheng)(sheng)(sheng)(sheng)物(wu)藥(yao)(yao),實現從(cong)概念到(dao)(dao)商業化生(sheng)(sheng)(sheng)(sheng)產的全(quan)(quan)過程(cheng)。公(gong)司通(tong)過高質量(liang)、一(yi)(yi)體化服(fu)務賦能全(quan)(quan)球客戶,提高研發效率,降低(di)研發成(cheng)本,進(jin)一(yi)(yi)步加速生(sheng)(sheng)(sheng)(sheng)物(wu)藥(yao)(yao)研發進(jin)程(cheng)。